{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:31:23Z","timestamp":1785879083903,"version":"3.56.0"},"reference-count":32,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>The aim of the present study was to evaluate whether previous preventive treatment with onabotulinumtoxin-A might influence subsequent clinical response following a switch to anti-CGRP monoclonal antibodies (mAbs). The present retrospective study was conducted at the Headache Centre\u2014Neurology Clinic at the Spedali Civili Hospital of Brescia between November 2018 and May 2023. The primary objective was to assess clinical outcome (monthly headache days (MHDs), monthly migraine days (MMDs), mean analgesics consumption, and clinical disability according to Migraine Disability Assessment (MIDAS)) following three months (T3) of preventive treatment with anti-CGRP mAbs comparing patients who did and those who did not previously receive treatment with Onabotulinumtoxin-A. Moreover, we aimed to evaluate whether the clinical response to anti-CGRP mAbs was affected by the number of previous Onabotulinumtoxin-A administrations. At T3, compared to Onabotulinumtoxin-A na\u00efve patients, patients who previously received Onabotulinumtoxin-A documented fewer MMDs (3.3 \u00b1 3.7 versus 5.2 \u00b1 5.0; p = 0.017) and a lower MIDAS score (23.2 \u00b1 20.9 versus 37.4 \u00b1 39.6; p = 0.013). Patients who received at least 3 onabotulinumtoxin-A administrations documented, at T3, lower MMDs compared to those who received fewer cycles (respectively, 2.1 \u00b1 2.7 vs. 6.5 \u00b1 4.4; p = 0.024). In conclusion, according to our data, previous treatment with onabotulinumtoxin-A might improve subsequent response to anti-CGRP mAbs preventive treatment.<\/jats:p>","DOI":"10.3390\/toxins15120677","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T09:37:54Z","timestamp":1701337074000},"page":"677","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine"],"prefix":"10.3390","volume":"15","author":[{"given":"Giulia","family":"Ceccardi","sequence":"first","affiliation":[{"name":"Department of Care Continuity and Frialty, Neurology Unit, University of Brescia, 25128 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Schiano di Cola","sequence":"additional","affiliation":[{"name":"Department of Care Continuity and Frialty, Neurology Unit, University of Brescia, 25128 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Caratozzolo","sequence":"additional","affiliation":[{"name":"Department of Care Continuity and Frialty, Neurology Unit, University of Brescia, 25128 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Di Pasquale","sequence":"additional","affiliation":[{"name":"Department of Care Continuity and Frialty, Neurology Unit, University of Brescia, 25128 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bolchini","sequence":"additional","affiliation":[{"name":"Department of Care Continuity and Frialty, Neurology Unit, University of Brescia, 25128 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Padovani","sequence":"additional","affiliation":[{"name":"Department of Care Continuity and Frialty, Neurology Unit, University of Brescia, 25128 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Care Continuity and Frialty, Neurology Unit, University of Brescia, 25128 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","article-title":"Migraine","volume":"8","author":"Ferrari","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"705276","DOI":"10.3389\/fpain.2021.705276","article-title":"Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives","volume":"2","author":"Mungoven","year":"2021","journal-title":"Front. Pain Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0333102414527648","article-title":"Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains","volume":"34","author":"Burstein","year":"2014","journal-title":"Cephalalgia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","article-title":"Guideline on the use of onabotulinumtoxinA in chronic migraine: A consensus statement from the European Headache Federation","volume":"19","author":"Bendtsen","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","article-title":"Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy","volume":"44","author":"Durham","year":"2004","journal-title":"Headache"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nbd.2012.07.010","article-title":"Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A","volume":"48","author":"Shimizu","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1177\/0333102419873675","article-title":"Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats","volume":"39","author":"Strassman","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: A phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","article-title":"Atogepant for the preventive treatment of chronic migraine (PROGRESS): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Ailani","year":"2023","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"10587","DOI":"10.1523\/JNEUROSCI.2211-17.2017","article-title":"Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (A\u03b4) But Not Unmyelinated (C) Meningeal Nociceptors","volume":"37","author":"Strassman","year":"2017","journal-title":"J. Neurosci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the Preventive Treatment of Chronic Migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/0333102419858355","article-title":"Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","article-title":"Fremanezumab in the prevention of high-frequency episodic and chronic migraine: A 12-week, multicenter, real-life, cohort study (the FRIEND study)","volume":"23","author":"Barbanti","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1007\/s10072-022-06154-0","article-title":"CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients","volume":"43","author":"Caratozzolo","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Scuteri, D., Tonin, P., Nicotera, P., Vulnera, M., Altieri, G.C., Tarsitano, A., Bagetta, G., and Corasaniti, M.T. (2022). Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine. Toxins, 14.","DOI":"10.3390\/toxins14080529"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/ene.15563","article-title":"Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study","volume":"30","author":"Vernieri","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s10194-016-0702-1","article-title":"Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year","volume":"17","author":"Rojo","year":"2016","journal-title":"J. Headache Pain"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Corbelli, I., Verzina, A., Leone De Magistris, I., De Vanna, G., Eusebi, P., Mataluni, G., Pisani, A., Prudenzano, A.M.P., Trojano, M., and Delussi, M. (2022). Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study. Toxins, 15.","DOI":"10.3390\/toxins15010034"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1007\/s10072-022-06195-5","article-title":"The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: A reliable option for the optimal treatment of chronic migraine","volume":"43","author":"Guerzoni","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"656294","DOI":"10.3389\/fneur.2021.656294","article-title":"Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine","volume":"12","author":"Silvestro","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/pm\/pnab093","article-title":"Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine","volume":"22","author":"Cohen","year":"2021","journal-title":"Pain Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Argyriou, A.A., Dermitzakis, E.V., Xiromerisiou, G., and Vikelis, M. (2022). OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine. Toxins, 14.","DOI":"10.3390\/toxins14120847"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/head.13843","article-title":"Dual Therapy with Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?","volume":"60","author":"Pellesi","year":"2020","journal-title":"Headache"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15360288.2020.1829249","article-title":"Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis","volume":"35","author":"Armanious","year":"2021","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","article-title":"Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review","volume":"10","author":"Blumenfeld","year":"2021","journal-title":"Pain Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"788159","DOI":"10.3389\/fneur.2021.788159","article-title":"Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine","volume":"12","author":"Mechtler","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_32","unstructured":"(2018). Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/12\/677\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:34:21Z","timestamp":1760132061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/12\/677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["toxins15120677"],"URL":"https:\/\/doi.org\/10.3390\/toxins15120677","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}